CALA
$2.69
Calithera Biosci Com
($.02)
(.74%)
CALA
Earnings Whisper ®
N/A
3rd Quarter September 2019
Consensus:  ($0.49)
Revenue:  N/A
Wednesday
Nov 6
4:05 PM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch

What do you expect when CALA reports earnings?
Beat
Meet
Miss

Where is CALA's stock price going from here?
Up
Flat
Down
Stock chart of CALA
Analysts
Summary of analysts' recommendations for CALA
Score
Grade
Pivots
Resistance
$2.83
$2.78
$2.74

$2.69

Support
$2.64
$2.59
$2.55
Tweet
Growth
Description
Calithera Biosciences, Inc. is a clinical-stage pharmaceutical company. It is focused on discovering and developing small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer. The Company's lead product candidate includes CB-839 which is in three Phase I clinical trials for the treatment of patients with solid tumors, leukemias, lymphomas, and multiple myeloma. Calithera Biosciences, Inc. is headquartered in South San Francisco, California.
Peers
Regeneron PharmaceuticalsCelgeneInterCeptVertex PharmaceuticalsBioMarin PharmaceuticalEndo International plcJohnson & JohnsonMylanZoetisPerrigo